Showing 1 - 7 of 7 Digestive System Diseases
A Multicenter, Randomized, Double-blind, Sham-controlled study for Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals with Type II Diabetes

Status: Open Not Enrolling

Investigator: Abhishek Kansara

Study Coordinator: Michelle Nguyen

Phone: 346.238.4586

This research study is designed to evaluate the safety and effectiveness of the ReCET™ device for improving glycemic (blood sugar) control in individuals with T2D. This study plans to enroll a minimum of 264 and a maximum of 350 participants ... Read more >

A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Safiya Joseph

Phone: 203.308.8567

The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). This st ... Read more >

A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Safiya Joseph

Phone: 203.308.8567

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also ... Read more >

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond Milan Criteria: A Feasibility Study

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Elsie Rizk

Phone: 713.441.2557

Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoemboli ... Read more >

DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH HYPERTRIGLYCERIDEMIA (MUIR-3 STUDY)

Status: Open Not Enrolling

Investigator: Abhishek Kansara

Study Coordinator: Zinah Rasheed

Phone: 713.363.7536

This is a multi-center, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of plozasiran injection in approximately 1328 adult subjects with HTG. After informed consent, subjects will be assessed for e ... Read more >

DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHASTA-3 STUDY)

Status: Open Not Enrolling

Investigator: Abhishek Kansara

Study Coordinator: Michelle Nguyen

Phone: 346.238.4586

This is a multi-center, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of plozasiran injection in approximately 1328 adult subjects with HTG. After informed consent, subjects will be assessed for e ... Read more >

Neoadjuvant Combination Therapy of Lenvima® plus Transcatheter Arterial Chemoembolization (TACE) for Transplant-Eligible Patients with Large Hepatocellular Carcinoma

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Elsie Rizk

Phone: 713.441.2557

We propose a regimen of six months neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria. Clinical, outcome ... Read more >